Hepatitis C genotype 3 disease

Kattakuzhy, Sarah; Levy, Rachel; Rosenthal, Elana; Tang, Lydia; Wilson, Eleanor; Kottilil, Shyam

doi:10.1007/s12072-016-9748-z

Cited by 28 publications

(25 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are six major clinical HCV genotypes and over 50 subtypes; however, genotype 3 infection represents a unique entity, with higher rates of steatosis and more rapid fibrosis progression [3]. In the direct acting antiviral (DAA) era, cure rates for genotype 3 infection have lagged behind the other genotypes until the approval of daclatasvir and sofosbuvir in 2015 and more recently, the approval of the fixed dose combination sofosbuvir and velpatasvir[4, 5]. This review will discuss the pathogenesis of accelerated fibrosis and current treatment options for HCV genotype 3 infection.…”

Section: Introductionmentioning

confidence: 99%

Genotype 3 Infection: The Last Stand of Hepatitis C Virus

Chan

Patel

Naggie

2017

Drugs

View full text Add to dashboard Cite

Hepatitis C Virus(HCV) represents a significant global disease burden with an estimated 130 – 150 million people worldwide living with chronic HCV infection. Within the 6 major clinical HCV genotypes, genotype 3 represents 22–30% of all infection, and is described as a unique entity with higher rates of steatosis, faster progression to cirrhosis, and higher rates of hepatocellular carcinoma. Hepatic steatosis in the setting of hepatitis C genotype 3 (HCV-3) is driven by viral influence on three major pathways: microsomal triglyceride transfer protein, sterol regulatory element-binding protein-1c, and peroxisome proliferator associated receptor-α. Historically with DAAs, the rates of cure for HCV-3 therapies lagged behind the other genotypes. As current therapies for HCV genotype 3 continue to close this gap, it is important to be cognizant of common drug interactions such as acid suppressing medication and amiodarone. In this review, we discuss the rates of steatosis in HCV-3, the mechanisms behind HCV-3 specific steatosis, and current and future therapies.

show abstract

Section: Introductionmentioning

confidence: 99%

Genotype 3 Infection: The Last Stand of Hepatitis C Virus

Chan

Patel

Naggie

2017

Drugs

View full text Add to dashboard Cite

show abstract

“…Sofosbuvir, an NS5B polymerase inhibitor, has a pan-genotypic anti-HCV activity and emerged as an important component of currently available anti-HCV regimens. It has been shown that patients with Genotype 3 have a higher risk for all worse outcomes compared to Genotype 2 or 1 (5). In registration trials, the effect of sofosbuvir containing regimens has been modest among patients with GT3 infection, especially in those with cirrhosis.…”

Section: Introductionmentioning

confidence: 99%

Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience

et al. 2017

View full text Add to dashboard Cite

Background: Documentation of the effectiveness of sofosbuvir and ribavirin with or without pegylated interferon alfa for hepatitis C virus Genotype 3 (HCV GT3) is limited in a real world setting.Objectives: The present study aimed at examining the outcome of the above therapy in a real world setting. Methods: Dual therapy of sofosbuvir and ribavirin was given for 24 weeks and triple therapy with additional pegylated interferon for 12 weeks. Patients received dual therapy when there was unwillingness to take interferon or interferon ineligibility.Results: In this analysis, 241 patients were included, of whom 175 were treated with dual and 66 with triple therapy. The mean age of the patients was 46.6 years, ranging from 20 to 72, and 136 (56.4%) were male. Clinical cirrhosis was present in 151 (62.7%) patients, and 98 (40.7%) had treatment experience. HCV RNA became negative in 225 (93.3%) patients at week 4 of the treatment. End of treatment virologic response was observed in 221 (91.7%) patients, and 199 (82.6%) had sustained virologic response 12 weeks post treatment (SVR12). Undetectable HCV RNA at week 4 was an independent parameter predicting SVR12 (P = 0.001). SVR12 was achieved in 143 (81.7%) patients treated with dual therapy and 56 (84.8%) with triple therapy (P = 0.567). Prior HCV treatment status and presence or absence of cirrhosis did not significantly affect the outcome between the 2 treatment groups. Conclusions:Treatment of HCV GT3 infection with the sofosbuvir and ribavirin with or without PEG-IFNα achieved durable responses in a significant number of cases in a real world setting.

show abstract

“…Resistance-associated variants (RAVs) may be present, despite being usually at low levels even before the beginning of DAAs treatment due to the great genetic variability of HCV [84]. Moreover, genotype 3 virus consistently demonstrates lower SVR rates to DAAs, despite higher SVR rates in other forms of the virus [85]. …”

Section: Do We Need Daas Resistance Testing In the Future?mentioning

confidence: 99%

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

Trucchi

Orsi

Alicino

et al. 2016

Journal of Immunology Research

View full text Add to dashboard Cite

Hepatitis C virus (HCV) still represents a major public health threat, with a dramatic burden from both epidemiological and clinical points of view. New generation of direct-acting antiviral agents (DAAs) has been recently introduced in clinical practice promising to cure HCV and to overcome the issues related to the interferon-based therapies. However, the emergence of drug resistance and the suboptimal activity of DAAs therapies against diverse HCV genotypes have been observed, determining treatment failure and hampering an effective control of HCV spread worldwide. Moreover, these treatments remain poorly accessible, particularly in low-income countries. Finally, effective screening strategy is crucial to early identifying and treating all HCV chronically infected patients. For all these reasons, even though new drugs may contribute to impacting HCV spread worldwide a preventive HCV vaccine remains a cornerstone in the road to significantly reduce the HCV spread globally, with the ultimate goal of its eradication. Advances in molecular vaccinology, together with a strong financial, political, and societal support, will enable reaching this fundamental success in the coming years. In this comprehensive review, the state of the art about these major topics in the fight against HCV and the future of research in these fields are discussed.

show abstract

Hepatitis C genotype 3 disease

Cited by 28 publications

References 38 publications

Genotype 3 Infection: The Last Stand of Hepatitis C Virus

Genotype 3 Infection: The Last Stand of Hepatitis C Virus

Sofosbuvir and Ribavirin With or Without Pegylated Interferon for Hepatitis C Genotype 3: A Real World Experience

State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization

Contact Info

Product

Resources

About